News | Published:

Genzyme, though unique, could be a bellwether for US biotech

Nature Medicine volume 17, page 145 (2011) | Download Citation

  • A Correction to this article was published on 07 March 2011

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 14 February 2011

     In the February 2011 issue, the article entitled "Genzyme, though unique, could be a bellwether for US biotech" (Nat. Med. 17, 145, 2011) incorrectly stated that GlaxoSmithKline had acquired AstraZeneca. Although GlaxoSmithKline has acquired medicines from AstraZeneca in the past, the two companies never merged. The error has been corrected in the HTML and PDF versions of the article.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0211-145

Authors

  1. Search for Elie Dolgin in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing